BR112017023190A2 - célula - Google Patents

célula

Info

Publication number
BR112017023190A2
BR112017023190A2 BR112017023190A BR112017023190A BR112017023190A2 BR 112017023190 A2 BR112017023190 A2 BR 112017023190A2 BR 112017023190 A BR112017023190 A BR 112017023190A BR 112017023190 A BR112017023190 A BR 112017023190A BR 112017023190 A2 BR112017023190 A2 BR 112017023190A2
Authority
BR
Brazil
Prior art keywords
protein
domain
binds
phosphorylated
immunoreceptor
Prior art date
Application number
BR112017023190A
Other languages
English (en)
Portuguese (pt)
Inventor
Kong Khai
PULÉ Martin
Cordoba Shaun
Thomas Simon
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of BR112017023190A2 publication Critical patent/BR112017023190A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112017023190A 2015-06-01 2016-05-31 célula BR112017023190A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein
PCT/GB2016/051576 WO2016193696A1 (en) 2015-06-01 2016-05-31 Cell

Publications (1)

Publication Number Publication Date
BR112017023190A2 true BR112017023190A2 (pt) 2018-07-17

Family

ID=53677545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023190A BR112017023190A2 (pt) 2015-06-01 2016-05-31 célula

Country Status (20)

Country Link
US (2) US11345734B2 (enExample)
EP (2) EP3730609A1 (enExample)
JP (4) JP6833727B2 (enExample)
KR (1) KR102275460B1 (enExample)
CN (1) CN107667170B (enExample)
AU (1) AU2016272457B2 (enExample)
BR (1) BR112017023190A2 (enExample)
CA (1) CA2986956C (enExample)
CL (1) CL2017003057A1 (enExample)
DK (1) DK3303568T3 (enExample)
ES (1) ES2791338T3 (enExample)
GB (1) GB201509413D0 (enExample)
HU (1) HUE050132T2 (enExample)
IL (1) IL255594B (enExample)
MX (1) MX383118B (enExample)
PL (1) PL3303568T3 (enExample)
PT (1) PT3303568T (enExample)
RU (1) RU2729158C2 (enExample)
WO (1) WO2016193696A1 (enExample)
ZA (1) ZA201707334B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
KR20240132100A (ko) 2015-07-28 2024-09-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
EA201891614A1 (ru) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы иммунотерапии
EP3402885A4 (en) * 2016-01-11 2019-07-03 The Board of Trustees of the Leland Stanford Junior University CHIMERIC PROTEINS AND METHOD FOR REGULATING GENE EXPRESSION
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
WO2018157000A1 (en) * 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity
EP3589647A1 (en) * 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN110621694A (zh) * 2017-05-15 2019-12-27 奥托路斯有限公司 包含嵌合抗原受体(car)的细胞
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
WO2019068066A1 (en) * 2017-09-29 2019-04-04 National Health Research Institutes METHODS AND COMPOSITIONS FOR IMPROVING THE SURVIVAL AND FUNCTIONALITY OF ANTI-TUMOR AND ANTI-VIRAL CELL LYMPHOCYTES
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
US20210189367A1 (en) * 2017-12-11 2021-06-24 Senti Biosciences, Inc. Inducible Cell Receptors for Cell-Based Therapeutics
WO2019243817A1 (en) * 2018-06-19 2019-12-26 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019392687A1 (en) 2018-12-06 2021-07-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
EP3914268B1 (en) 2019-01-23 2025-10-15 Miltenyi Biotec B.V. & Co. KG A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
MA55896A (fr) * 2019-05-07 2022-03-16 Modernatx Inc Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
CN112279922B (zh) * 2019-07-22 2023-07-28 南京助天中科科技发展有限公司 一种吞噬细胞嵌合抗原受体及其应用
CA3149897A1 (en) 2019-09-03 2021-03-11 Daniel Getts Methods and compositions for genomic integration
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US20230151373A1 (en) * 2019-10-23 2023-05-18 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
US20220389075A1 (en) * 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
MX2022006962A (es) * 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
IL298693A (en) 2020-06-04 2023-02-01 Carisma Therapeutics Inc New structures for chimeric antigen receptors
US20230250149A1 (en) * 2020-06-25 2023-08-10 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
LT4058474T (lt) 2020-08-20 2024-08-26 A2 Biotherapeutics, Inc. Kompozicijos ir būdai, skirti gydyti egfr atžvilgiu teigiamas vėžio formas
MX2023002041A (es) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
WO2022093741A1 (en) * 2020-10-26 2022-05-05 Research Development Foundation Mutant proteases and uses thereof
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN118703444A (zh) * 2021-01-22 2024-09-27 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
IL308445A (en) 2021-05-11 2024-01-01 Myeloid Therapeutics Inc Methods and compositions for genomic integration
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
CA3236268A1 (en) * 2021-11-04 2023-05-11 Jens G. LOHR Developing inducible cluster chimeric antigen receptor (ccar) constructs
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
JPH11507824A (ja) * 1995-06-07 1999-07-13 ユニバーシティー・オブ・ペンシルバニア 食作用を阻害する方法
US6303319B1 (en) 1996-02-23 2001-10-16 Ariad Pharmaceuticals, Inc. Cell based assay for identifying sh2-domain-specific signal transducer antagonist
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
KR102466666B1 (ko) * 2013-03-15 2022-11-15 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
MX373687B (es) 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
PL3597742T3 (pl) * 2014-10-09 2022-11-14 Yamaguchi University Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Also Published As

Publication number Publication date
ES2791338T3 (es) 2020-11-03
PT3303568T (pt) 2020-06-08
AU2016272457A1 (en) 2017-12-14
US20190023761A1 (en) 2019-01-24
US11345734B2 (en) 2022-05-31
CA2986956A1 (en) 2016-12-08
MX383118B (es) 2025-03-13
RU2017145074A (ru) 2019-07-09
JP2018517410A (ja) 2018-07-05
ZA201707334B (en) 2020-02-26
US20220267404A1 (en) 2022-08-25
WO2016193696A1 (en) 2016-12-08
EP3303568B1 (en) 2020-05-06
HK1246825A1 (en) 2018-09-14
CA2986956C (en) 2022-03-22
JP6833727B2 (ja) 2021-02-24
DK3303568T3 (da) 2020-07-06
PL3303568T3 (pl) 2020-11-02
JP2020115898A (ja) 2020-08-06
IL255594A (en) 2018-01-31
RU2729158C2 (ru) 2020-08-04
MX2017014630A (es) 2018-06-06
IL255594B (en) 2020-11-30
JP2024149818A (ja) 2024-10-18
NZ737662A (en) 2021-10-29
CL2017003057A1 (es) 2018-03-16
GB201509413D0 (en) 2015-07-15
EP3303568A1 (en) 2018-04-11
AU2016272457B2 (en) 2020-12-10
KR102275460B1 (ko) 2021-07-14
HUE050132T2 (hu) 2020-11-30
EP3730609A1 (en) 2020-10-28
RU2017145074A3 (enExample) 2019-07-17
JP2022066380A (ja) 2022-04-28
CN107667170A (zh) 2018-02-06
KR20180012762A (ko) 2018-02-06
CN107667170B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
BR112017023190A2 (pt) célula
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
MX2021012720A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
BR112018009129A2 (pt) receptores de antígeno quimérico que visam her2
EA201792042A1 (ru) T-клетка, которая экспрессирует t-клеточный рецептор (tcr) гамма-дельта и химерный антигенный рецептор (car)
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
MA49038B1 (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
BR112017018252A2 (pt) receptores de antígenos quiméricos
UY31504A1 (es) Construcciones de union de antigenos
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
BR112017013690A2 (pt) célula
EP3759145A4 (en) Diagnostic methods using anti-muc1* antibodies
BR112016022910A2 (pt) anticorpos contra her2 biespecíficos
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
CL2021002238A1 (es) Inhibidores de la vía de respuesta integrada al estrés.
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
EP3522718A4 (en) FOR ICAM-1 SPECIFIC CHIMERIC ANTIGEN RECEPTOR OF THE I DOMAIN

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UCL BUSINESS LTD. (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: AUTOLUS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: AUTOLUS LIMITED (GB)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2798 DE 20/08/2024 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025000772-2 PROTOCOLO 870250003367 EM 15/01/2025 15:20.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]